Evidence map›Paper›PMID 33241032›Full record

ArticleAnnals of translational medicine2020

Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of

Xin Huang, Jia-Qi Liu, Yi-Dong Zhou, Ying Xu, Chang Chen, Xiang Wang, Xi Cao, Ru Yao, Qiang Sun

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xin HuangDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Jia-Qi LiuDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yi-Dong ZhouDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Ying XuDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Chang ChenDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Xiang WangDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xi CaoDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Ru YaoDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Qiang SunDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Peking Union Medical College Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsPatients who underwent SLNB at initial were enrolled and divided according to

resultsAccording to

conclusionsSLNB should be considered for clinically node-negative breast cancer regardless of

Indexed as

BRCA1/2 mutationclinically node-negative breast cancerSentinel lymph node biopsy (SLNB)sentinel lymph node involvement rate (SLN involvement rate)survival

Identifiers

PMID33241032
PMCPMC7576024
OpenAlexW3088957420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.